Jesus Penabad, MD
Endocrinology, Diabetes & Metabolism · Hudson, FLNPI 1285637553
Payments from drug & device makers
Across 706 payments — averaging $226.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$129K
- Johnson & Johnson$10K
- Dompe Farmaceutici S.p.a.$6K
- Novo Nordisk$2K
- Amgen$1K
- Sanofi-aventis U.S. LLC$1K
- plus $10K from 50 others
What the payments were for
- Speaking & faculty fees$9,89540%
- Food & beverage$14,76160%
- Education$770%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVOKANA$9,765
- iLet Bionic Pancreas$802
- Ozempic$347
- EVENITY$326
- MINIMED 780G$291
- t-slim insulin pump$250
- Korlym$247
- iLet Insulin Infusion Kit Inset$145
- iLet Insulin Infusion Kit Contact Detach$145
- Omnipod$139
- TZIELD$134
- NEXLIZET$125
- NEXLETOL$125
- MOUNJARO$118
- Kerendia$113
- Eversense$106
How this compares
$160,210 in reported general payments places this provider in the 90th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 560 | $723,189 |
| KorlymMifepristone | 14 | $684,219 |
| JardianceEmpagliflozin | 325 | $380,339 |
| MounjaroTirzepatide | 129 | $184,718 |
| Tresiba Flextouch U-100Insulin Degludec | 245 | $176,307 |
| TrulicityDulaglutide | 93 | $156,396 |
| RybelsusSemaglutide | 72 | $154,785 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 87 | $126,190 |
| JanuviaSitagliptin Phosphate | 73 | $88,637 |
| Humulin R U-500Insulin Regular, Human | 50 | $73,984 |
| ProliaDenosumab | 42 | $72,935 |
| Tresiba Flextouch U-200Insulin Degludec | 53 | $68,984 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 80 | $67,729 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $59,520 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 54 | $55,696 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $2,274 | $933,174728 claims |
| Corcept TherapeuticsKorlym | $1,100 | $684,21914 claims |
| Boehringer IngelheimJardiance, Tradjenta | $356 | $393,129337 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $901 | $363,133278 claims |
| MerckJanuvia | $306 | $88,63773 claims |
| AmgenProlia | $1,471 | $72,93542 claims |
| Johnson & JohnsonInvokana | $9,973 | $45,19539 claims |
| AstraZenecaFarxiga | $429 | $32,73531 claims |
| BayerKerendia | $789 | $13,42611 claims |
| AbbVieSynthroid | $46 | $7,22684 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $126 | $5,854616 claims |
| Sanofi-aventis U.S. LLCLantus | $1,188 | $5,50932 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Hudson
- Antonio Pinero PilonaHudson$2M
- Ania JanickaHudson$475K
- Anna Szafran-SwietlikHudson$340K
- Richard PratleyOrlando$9.2M
- Jose MandryOcoee$9.1M
- Steven SmithOrlando$7.9M
- Barry HorowitzWest Palm Beach$7.1M
- Tina ThethiOrlando$3.8M
- David SuttonJacksonville$3.1M
- Lorena Lewy-AlterbaumHollywood$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.